Valuation: CSPC Pharmaceutical Group Limited

Market Cap 109B 13.88B 11.88B 11.11B 10.18B 19.12B 1,328B 19.52B 131B 51.26B 667B 52.11B 50.97B 2,207B P/E 2026 *
11.5x
P/E 2027 * 15.6x
Enterprise Value 89.49B 11.41B 9.77B 9.13B 8.37B 15.72B 1,092B 16.05B 108B 42.15B 549B 42.84B 41.91B 1,815B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 2.71x
Free-Float
67.42%
Yield 2026 *
2.78%
Yield 2027 * 3.84%
08-20 Pharma sector doubles down on AI amid hopes of slashing costs, timelines RE
08-20 CSPC Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-20 CSPC Pharmaceutical's Attributable Profit More Than Doubles in H1; Shares Jump 14% MT
08-18 CSPC Pharma Unit's Breast Cancer Drug Application Granted Priority Review in China MT
08-12 CSPC Pharmaceutical Group Limited Provides Update on the Collaboration, Option and License Agreement with Astrazeneca for the Development of siRNA Drugs CI
08-12 CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus MT
08-11 CSPC Pharmaceutical Group Limited Initiates Phase I Clinical Trial Of SYS6063 For Treatment Of Relapsed, Refractory Systemic Lupus Erythematosus At First Centre In China CI
08-10 CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA MT
08-10 CSPC Pharmaceutical Group Limited Announces SYS6037 Injection MPOX MRNA Vaccine Obtains Clinical Trial Approval In The U S CI
08-05 CSPC Pharma Gets $10 Million Milestone Payment from AstraZeneca Under Research Deal MT
08-05 CSPC Pharma, AstraZeneca Form JV to Build Biologics Manufacturing Facility in China MT
08-05 CSPC Pharmaceutical Group Limited Announces Receipt of USD 10 Million Milestone Payment Under the Strategic Research Collaboration Agreement with Astrazeneca CI
08-05 CSPC Pharmaceutical Group Limited And AstraZeneca Enter Into Joint Venture Contract For Establishment Of Joint Venture To Further Deepen Strategic Collaboration CI
1 day+9.61%
1 week+9.74%
Current month+10.96%
1 month+17.53%
3 months+27.79%
6 months-7.12%
Current year+12.93%
1 week 8.61
Extreme 8.61
10.17
1 month 8.21
Extreme 8.21
10.17
Current year 6.53
Extreme 6.53
10.96
1 year 6.53
Extreme 6.53
11.63
3 years 4.27
Extreme 4.27
11.63
5 years 4.27
Extreme 4.27
11.63
10 years 3.61
Extreme 3.609374
13.93
Manager TitleAgeSince
Chief Executive Officer 46 18/12/2025
Chief Operating Officer 56 18/12/2025
Corporate Officer/Principal 44 30/06/2024
Director TitleAgeSince
Chairman 72 25/08/2011
Director/Board Member 56 19/01/2012
Director/Board Member 66 20/12/2012
Date Insider Type Main position Quantity % Market Cap.
23/06/26 Other

Director

-700,000 0.0061%
23/12/25 Other

Chairman

6,706,000 0.0582%
25/11/25 Other

Chairman

10,300,000 0.0894%
Change 5-day change 1-year change 3-year change Capi.($)
+9.61%+9.74%-10.53%+68.50% 12.66B
-2.81%+1.98%+76.96%+127.73% 1,141B
-2.21%+2.50%+50.38%+55.01% 659B
-1.56%+5.25%+26.98%+74.39% 470B
+1.20%+1.72%+42.89%+45.78% 366B
-0.61%+1.72%+25.21%+41.34% 302B
+0.32%+3.30%+2.60%+13.42% 254B
-1.95%+4.22%+46.75%+65.66% 239B
-1.10%-1.12%-14.91%-52.66% 207B
-2.82%+5.57%+21.58%+89.04% 183B
Average +0.50%+3.71%+26.79%+52.82% 383.36B
Weighted average by Cap. -0.06%+4.30%+44.24%+70.85%

Financials

2026 *2027 *
Net sales 39.69B 5.06B 4.33B 4.05B 3.71B 6.97B 484B 7.12B 47.93B 18.69B 243B 19B 18.59B 805B 35.21B 4.49B 3.84B 3.59B 3.29B 6.19B 430B 6.32B 42.52B 16.58B 216B 16.86B 16.49B 714B
Net income 10.4B 1.33B 1.14B 1.06B 973M 1.83B 127B 1.86B 12.55B 4.9B 63.75B 4.98B 4.87B 211B 6.89B 878M 752M 703M 644M 1.21B 84.04B 1.24B 8.32B 3.24B 42.23B 3.3B 3.23B 140B
Net Debt -19.35B -2.47B -2.11B -1.97B -1.81B -3.4B -236B -3.47B -23.37B -9.12B -119B -9.27B -9.06B -392B -13.31B -1.7B -1.45B -1.36B -1.25B -2.34B -162B -2.39B -16.08B -6.27B -81.63B -6.37B -6.23B -270B
Logo CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
19,700
Date Price Change Volume
20/08/26 HK$9.520 +9.61% 439,742,523
19/08/26 HK$8.685 -1.31% 67,351,804
18/08/26 HK$8.800 +0.51% 49,361,265
17/08/26 HK$8.755 +0.75% 70,421,131
14/08/26 HK$8.690 -1.81% 39,418,434
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
9.520HKD
Average target price
11.81HKD
Spread / Average Target
+24.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1093 Stock